Research Projects Page

This study assess the impact of pharmacist-led tailored monitoring for patients initiating encorafenib and binimetinib combination therapy. A retrospective study showed that in the first 90 days of treatment 44% of patients required at least 1 treatment interruption, 39% required at least 1 dose reduction, 11% discontinued therapy. A prospective study reporting the impact of implementing a pharmacist-led targeted monitoring program is forthcoming.

This study examins the use and pharmacotherapy of direct acting antivirals to treat hepatitis C in transplant patients receiving positive donor hearts. While results of this practice have proven successful, management of drug-drug interactions between transplant medications and DAAs is necessary to ensure safety and efficacy.

This study of patients with RMS and ≥3 fills of DMT from a health-system specialty pharmacy evaluated DMT persistence. The probability of remaining persistent for 3 years was 0.51. Non-persistent patients mostly switched to a new DMT (39%), discontinued the DMT (26%) discontinued, or transferred care to a new specialty pharmacy or provider (27%). Specialty pharmacists played a key role in DMT transitions and initiated 7% of DMT discontinuations and 36% of DMT switches.

This study evaluates PCSK9i persistence at 2, 12 and 24 months after initiation of therapy, reasons for non-persistence and percent change in LDL.

This two-part study aimed to identify the rates and reasons of PMN for specialty oral oncolytic agents. In Part I, we used 24 methods to calculate PMN based on combinations of three parameters. In Part II, we reviewed electronic medical records of 198 prescriptions considered PMN by our previous calculation.

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.

This study evaluated access and affordability of HIV PrEP in patients seen at a multidisciplinary PrEP clinic. In this cohort of mostly commercially insured men, the majority were able to access PrEP with low out-of-pocket costs facilitated by manufacturer assistance. Although generalizability beyond this population is limited, these results contradict perceived financial barriers to PrEP access.

This case series describes the safety and effectiveness outcomes of patietns requiring HCV DAA tablet manipulation. This data along with a comprehensive review of other reports of DAA manipulation demonstrate the safety and efficacy of tablet manipulation.

In this study, we found the time to access pimavanserin reduced by 21 days on average after pharmacist integration. Similarly, the rate of third party approval increased by 16% and treatment initiation increased by 18%.

This study retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Sixty-three patients were identified. All patients failed at least on prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn's disease. Significant clinical and endoscopic response was seen. Adherence was high in a cohort with high refractory disease.